ESMO 2019 | REACH safety data: avelumab plus RT-cetuximab in LA SCCHN

Jean Bourhis

Jean Bourhis, MD, PhD, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, speaks at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain. Dr Bourhis discusses the safety and toxicity seen in the REACH study (NCT02999087) – a trial evaluating the use of avelumab when combined with cetuximab and radiation therapy in locally advanced squamous cell carcinoma of the head and neck (LA SCCHN).

Share this video